Sequential requirements for distinct Polθ domains during theta-mediated end joining dlvr.it/T5kL0F

📢One of the best annual events in Cancer Research is coming! Great speakers, excellent scientific content...get ready for the next EACR Congress!
📅Save the date: 10-13 June 2024 in Rotterdam!
👉Early Rate Registration: 29/04/24
👉Regular Rate Registration: 27/05/24

Esta semana hemos sabido que identifican nuevos biomarcadores de imagen para predecir la respuesta al tratamiento en pacientes con cáncer de próstata con metástasis óseas

🗞️ Los resultados del estudio #iPROMET se han publicado en European Urology ➡️  linke.to/iPROMETCASTVHIO

Registration is open for #EACR2024 at #Rotterdam
Great line-up of speakers!
Much to learn for the next-generation 😉.

Find out more here: 2024.eacr.org
EACR

cell.com/cell-reports/f…
Big milestone for my lab, separating functions of the BRCA pathway in reprogramming. Primary role is repair of the replication-associated DSB by HDR. More efficient HDR through 53BP1 loss improves reprogramming. This project took only 10 years! Congrats to…

🚀 Excited to announce our latest Cell publication on 'Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.'
An important collaboration shedding light on promising avenues in cancer research.📑✨
sciencedirect.com/science/articl…

'Embracing #cancer complexity: Hallmarks of systemic disease'

It was a privilege to contribute to this #Cell review, with an incredible group of scientists!

Our forward-looking perspective ⬇️ - incl. the #tumor #microenvironment as a critical target 🎯

cell.com/cell/fulltext/…

📺La Dra. Mònica Sánchez Guixé ( #IRBBarcelona ) y el Dr. Jaume Mora (@IRSJD_info), en RTVE.

🧬Conoce el último trabajo publicado en Cancer Discovery por el que se desvela el origen de segundos cánceres pediátricos y las mutaciones de la quimioterapia en los tejidos sanos.

#PediatricCancer bbglab

This narrative review summarizes the literature supporting the use of PARP inhibitors for breast cancer treatment, as well as potential future research directions. ja.ma/4ai7lDf

Online Now: Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy dlvr.it/T4QtqZ

VHIO pone en marcha con éxito el programa de divulgación #VHIO4STEM para fomentar vocaciones científicas entre chicos y chicas de 4º de ESO. 

➡️ linke.to/VHIO4STEM

🔬 #IRBBarcelona & Institut de Recerca Sant Joan de Déu researchers unveil the origin of second #PediatricCancers & #chemotherapy -induced mutations in healthy tissues.

📰Cancer Discovery

✍️ Mònica Sánchez Guixé Alexandra Avgustinova abeldavidgp Nuria Lopez-Bigas et al.

➡️shorturl.at/iwNUY

📌doi.org/10.1158/2159-8…

#IRBScience

Our latest paper published in Cancer Discovery.

Stress-induced metastasis: The NET effect dlvr.it/T47r5v

¿Cómo abordamos la resistencia a inhibidores de PARP en #cáncer demama BRCA? Seguimos aprendiendo sobre opciones terapéuticas dirigidas en #cáncer de mama hereditario con esta ponencia de la Dra. Violeta Serra de Vall d’Hebron Institute of Oncology (VHIO) #JornadaCMH24 SOLTI #cancerresearch SEOM

New algorithm for Mutational Signature analysis:
Accurate and sensitive mutational signature analysis with MuSiCal
nature.com/articles/s4158…

And comment: Improved identification of cancer mutational processes
nature.com/articles/s4158…

Nature Genetics

📢 Exciting news from our group @RadiomicsVHIO & @HUBellvitge!
🧠We have developed a tool to differentiate between different types of neurological tumors using MRI data.
📎 Paper (Cell Reports Medicine): doi.org/10.1016/j.xcrm…
👩‍💻 Code: github.com/radiomicsgroup…

Feeding two birds with one scone: The dual roles of SMARCAL1 in antitumor immunity dlvr.it/T3wXfB

Most viewed in the last 7 days from JAMA Oncology:

Is bilateral oophorectomy associated with a decreased risk of death among women with a BRCA1 or BRCA2 sequence variation?

ja.ma/49HhpW0

🧬 ¿Tienes una variante patogénica en el gen BRCA1? 🙋‍♀️ Ayúdanos a prevenir el #CáncerDeMama en las mujeres con un riesgo más elevado. Participa en el #EnsayoClínico BRCA-P 🔬

📱972 22 58 28 
👩‍💻 reec.aemps.es
 
Institut Català d'Oncologia Vall d'Hebron Vall d’Hebron Institute of Oncology (VHIO) HSP @iibsantpau